Air Force prepares for release of newly approved Novavax COVID-19 vaccine

  • Published
  • By 932nd Airlift Wing Public Affairs

The Food and Drug Administration (FDA) recently granted the Novavax COVID-19 Vaccine Emergency Use Authorization (EUA) and the Centers for Disease Control and Prevention (CDC) has endorsed it as a primary series option for adults ages 18 years and older. 

The Novavax COVID-19 vaccine, which will be available in the coming weeks, is a two-dose vaccine that presents a new option for those who have been reluctant to receive the FDA fully licensed and approved mRNA vaccines, Pfizer Cominarty and Moderna Spikevax.

Service members who voluntarily immunize with the Novavax COVID-19 vaccine meet the requirement for COVID-19 vaccination.

The Novavax COVID-19 Vaccine secured World Health Organization (WHO) Emergency Use Listing (EUL) in December 2021 with availability outside of the U.S. 

In accordance with the September 3, 2021 Secretary of the Air Force Mandatory COVID-19 Vaccination of Air Force Military Members Memorandum (para 3) and March 14, 2022 COVID-19 Mandatory Vaccination Implementation Guidance for DAF Service Members (para 1.2.5), service members voluntarily immunized with any FDA Approved, FDA Emergency Use Authorized (EUA), or WHO Emergency Use Listing (EUL) COVID-19 vaccine IAW applicable dose requirements are considered fully vaccinated.

Members can obtain Novavax from retail pharmacies.  If so, they need to submit their immunization record information to their medical unit for uploading into Aeromedical Services Information Management System (ASIMS).  Link to the vaccine finder is Vaccine Finder.

Related Air Force News Article:

Air Force prepares for newly approved COVID-19 vaccine: Novavax provides new option for unvaccinated Airmen, Guardians